Research analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Thursday. The stock has a market cap of $100,084.00, a PE ratio of -0.02 and a beta of 1.47. Navidea Biopharmaceuticals has a 52-week low of $0.00 and a 52-week high of $0.15.
About Navidea Biopharmaceuticals
Featured Articles
- Five stocks we like better than Navidea Biopharmaceuticals
- Transportation Stocks Investing
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- What Are Dividends? Buy the Best Dividend Stocks
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Breakout Stocks: What They Are and How to Identify Them
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.